Paul J Maddon
Overview
Explore the profile of Paul J Maddon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
1187
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dhody K, Pourhassan N, Kazempour K, Green D, Badri S, Mekonnen H, et al.
HIV Clin Trials
. 2018 Apr;
19(3):85-93.
PMID: 29676212
Background PRO 140 is a humanized monoclonal antibody targeting CCR5 with potent antiviral activity in patients with CCR5-tropic HIV-1 infection. In phase 2b studies, we evaluated the long-term efficacy, safety,...
2.
Marozsan A, Ma D, Nagashima K, Kennedy B, Kang Y, Arrigale R, et al.
J Infect Dis
. 2012 Jun;
206(5):706-13.
PMID: 22732923
The spore-forming bacterium Clostridium difficile represents the principal cause of hospital-acquired diarrhea and pseudomembranous colitis worldwide. C. difficile infection (CDI) is mediated by 2 bacterial toxins, A and B; neutralizing...
3.
Coburn G, Fisch D, Moorji S, de Muys J, Murga J, Paul D, et al.
PLoS One
. 2012 May;
7(4):e35351.
PMID: 22545104
Combinations of direct-acting anti-virals offer the potential to improve the efficacy, tolerability and duration of the current treatment regimen for hepatitis C virus (HCV) infection. Viral entry represents a distinct...
4.
Jacobson J, Lalezari J, Thompson M, Fichtenbaum C, Saag M, Zingman B, et al.
Antimicrob Agents Chemother
. 2010 Jul;
54(10):4137-42.
PMID: 20660677
The anti-CCR5 antibody PRO 140 has shown potent and prolonged antiretroviral activity in subjects infected with CCR5-tropic (R5) HIV-1. Prior studies have examined single intravenous doses ranging up to 5...
5.
Jacobson J, Thompson M, Lalezari J, Saag M, Zingman B, DAmbrosio P, et al.
J Infect Dis
. 2010 Apr;
201(10):1481-7.
PMID: 20377413
Background: PRO 140 is a humanized CCR5 monoclonal antibody that has demonstrated potent antiviral activity when it is administered intravenously to adults infected with CCR5-tropic (R5) human immunodeficiency virus type...
6.
Kang Y, Andjelic S, Binley J, Crooks E, Franti M, Iyer S, et al.
Vaccine
. 2009 Jul;
27(37):5120-32.
PMID: 19567243
SOSIP gp140 trimers represent a soluble, stabilized, proteolytically cleaved form of the HIV-1 envelope (Env) glycoproteins. SOSIP gp140 derived from a subtype A HIV-1 isolate, KNH1144, forms exceptionally stable trimers...
7.
Jacobson J, Saag M, Thompson M, Fischl M, Liporace R, Reichman R, et al.
J Infect Dis
. 2008 Sep;
198(9):1345-52.
PMID: 18771406
Background: The current goal of human immunodeficiency virus type 1 (HIV-1) therapy is to maximally suppress viral replication. Securing this goal requires new drugs and treatment classes. The chemokine receptor...
8.
Durso R, Andjelic S, Gardner J, Margitich D, Donovan G, Arrigale R, et al.
Clin Cancer Res
. 2007 Jul;
13(13):3999-4008.
PMID: 17606734
Purpose: Prostate-specific membrane antigen (PSMA) is an attractive target for active immunotherapy. Alphavirus vaccines have shown promise in eliciting immunity to tumor antigens. This study investigated the immunogenicity of alphavirus...
9.
Iyer S, Franti M, Krauchuk A, Fisch D, Ouattara A, Roux K, et al.
AIDS Res Hum Retroviruses
. 2007 Jul;
23(6):817-28.
PMID: 17604546
HIV type 1 (HIV-1) envelope is a noncovalent trimer of gp120-gp41 heterodimers, and its lability has hindered structural studies. SOSIP gp140 is a soluble, proteolytically mature form of the HIV-1...
10.
Beddows S, Franti M, Dey A, Kirschner M, Iyer S, Fisch D, et al.
Virology
. 2006 Nov;
360(2):329-40.
PMID: 17126869
The human immunodeficiency virus type 1 (HIV-1) surface envelope glycoprotein (Env) complex, a homotrimer containing gp120 surface glycoprotein and gp41 transmembrane glycoprotein subunits, mediates the binding and fusion of the...